Lexaria Applauds FDA Decision on Reduced Risk Tobacco Format

Author's Avatar
Oct 24, 2019
Article's Main Image

KELOWNA, BC / ACCESSWIRE / October 24, 2019 / Lexaria Bioscience Corp. (OTCQX:LXRP, Financial) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is very pleased to report that, for the first time ever, the Food and Drug Administration (the "FDA") has authorized the marketing of oral nicotine products through the Modified Risk Tobacco Product pathway, including product categories that could benefit from Lexaria's technology.